help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masuda, A.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masuda, A.
Right arrow Articles by Takahashi, T.
(American Journal of Pathology. 2001;158:87-96.)
© 2001 American Society for Investigative Pathology

Regular Articles

Protective Function of p27KIP1 against Apoptosis in Small Cell Lung Cancer Cells in Unfavorable Microenvironments

Akira Masuda*, Hirotaka Osada*, Yasushi Yatabe{dagger}, Ken-ichi Kozaki*, Yoshio Tatematsu*, Takao Takahashi*, Toyoaki Hida{ddagger}, Toshitada Takahashi§ and Takashi Takahashi*

From the Divisions of Molecular Oncology*
and Immunology,§
Aichi Cancer Center Research Institute, Nagoya; and the Departments of Pathology and Clinical Laboratories{dagger}
and Pulmonary Medicine,{ddagger}
Aichi Cancer Center Hospital, Nagoya, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
A previous study of ours unexpectedly found that in contrast to frequent reductions in non-small cell lung cancer, high expression of the p27KIP1 cyclin-dependent kinase (CDK) inhibitor was retained in virtually all small cell lung cancers (SCLCs), suggesting the possibility of high expression of nonfunctional p27KIP1 in this virulent tumor. The study presented here, however, shows that p27KIP1 in SCLC biochemically functions as a CDK inhibitor, clearly showing induction apparently associated with G1/G0 arrest and efficient binding to and inhibition of the cyclin E-CDK2 complex. Interestingly, induction of p27KIP1 seems to confer on SCLC cells the ability to survive under culture conditions unfavorable for cell growth such as a lack of nutrients and hypoxia. Subsequent experiments manipulating p27KIP1 levels by using a sense p27KIP1 expression construct or an antisense oligonucleotide supported this notion. These observations suggest that high expression of p27KIP1 in vivo may favor the survival of SCLC by preventing apoptosis in a microenvironment unfavorable for cell proliferation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Lung cancer is among the leading causes of cancer death in economically developed countries. It is classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which exhibit considerably distinct clinicopathological, biological, and molecular genetic characteristics.1,2 Prognosis of SCLC cases is generally worse than that of NSCLC patients because of the former’s propensity for earlier aggressive growth and metastasis. Recent studies on cell cycle control in relation to carcinogenesis have revealed that cyclin-dependent kinase (CDK) inhibitors, which negatively regulate the ordered activation of cyclin-CDK complexes during the cell cycle, may play a role as tumor suppressor genes.3 For example, genetic and epigenetic inactivation of the p16 gene has been reported in various human cancers including NSCLC,4-7 whereas a previous report of ours suggested the potential involvement of the imprinted p57KIP2 gene in the development of lung cancers because of selective loss of the active maternal allele.8

p27KIP1, a member of the CIP/KIP CDK inhibitor family, is expressed in large amounts in quiescent cells and declines before cellular proliferation in response to mitogenic signals.9 Although p27KIP1 may also function as a potential tumor suppressor gene, virtually no somatic mutations have been reported in human neoplasms thus far.10,11 We previously reported that significantly reduced p27KIP1 expression is frequent in NSCLC and associated with shortened patient survival. On the other hand, high p27KIP1 expression was unexpectedly detected in virtually all cases of SCLC, which is known to be the most virulent type of human lung cancer.12 This observation could not be easily reconciled with this inhibitor’s function as a negative regulator of the cell cycle, and raised the possibility that highly expressed p27KIP1 in SCLC may be in a nonfunctional state because of multiple genetic defects such as myc gene amplification and Rb inactivation. In this connection, Vlach and colleagues13 reported that c-myc could abrogate growth arrest by sequestering p27KIP1 in a form that cannot bind the cyclin E-CDK2 complex. Alternatively, the almost invariably occurring inactivation of Rb, which is negatively regulated by the cyclin-CDK complexes, might allow SCLC cells to proliferate in the presence of high p27KIP1 expression.

In the study presented here, we examined the regulation and functions of highly expressed p27KIP1 in SCLC as well as its biological consequences. We were able to show that p27KIP1 can be induced by unfavorable changes in the cellular microenvironment such as nutrient insufficiency and low oxygen pressure, that it is biochemically functional as a CDK inhibitor in apparent association with G1/G0 arrest, and that it confers on SCLC cells the ability to escape from apoptosis under conditions unfavorable for cell growth. Therapeutic implications of these observations are also discussed.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell Culture

RPMI 1640 powder and the selectamine kit for preparation of the isoleucine-free medium were purchased from Life Technologies, Inc. (Gaithersburg, MD) and fetal calf serum (FCS) from JRH Bioscience (Lenexa, KS). The human SCLC cell lines, ACC-LC-35, -48, -49, -51, and -67, were established in our laboratory14 and kept in a plastic flask for suspension culture (Sumilon MS-2005R; Sumitomo Bakelite, Tokyo, Japan). Twice a week the cell lines were supplied with RPMI 1640 medium supplemented with 5% FCS. Molecular genetic studies have demonstrated the inactivation of the Rb and p53 genes and amplification of the L-myc gene in ACC-LC-48 and ACC-LC-49. For immunohistochemical, biochemical, and fluorescence-activated cell sorting (FACS) analyses, 5 x 105 cells were inoculated in 35-mm dishes for suspension culture (Falcon 1008; Becton Dickinson, Bedford, MA) with either complete or isoleucine-free RPMI 1640 medium supplemented with dialyzed 5% FCS and 0.65% methylcellulose (4000 cps; Katayama Chemical, Osaka, Japan) and incubated at 37°C for given periods. Hypoxic conditions were generated with an anaerobic sealed bag and an anaerobic culture system consisting of oxygen absorber, CO2 generator, and oxygen indicator (FX-4; Cosmo Bio Co., Ltd., Tokyo, Japan). With this system, it was possible to keep and monitor the oxygen concentration at <0.1%.

Transplantation

Five-week-old female SCID mice were purchased from the Shizuoka Laboratory Animal Center (Hamamatsu, Japan) and maintained under specific pathogen-free conditions. Approximately 1 x 107 SCLC cells in 100 µl of serum-free RPMI 1640 medium were injected in the subcutaneous tissue of the left abdominal wall of the mice. Tumors developed within 2 weeks. The mice were sacrificed 3 weeks after the injection and the cells from the dissected tumors were immediately minced and used for an autoradiography experiment.

Immunocytochemistry

Aggregates of SCLC cells in suspension culture were dissociated with 0.05% ethylenediaminetetraacetic acid in phosphate-buffered saline (PBS) for 5 minutes, attached to a glass slide by centrifugation with an Auto Smear CF-12D (Sakura, Tokyo, Japan), briefly air-dried, and then fixed with 4% formalin in PBS. The slides were incubated with anti-p27KIP1 monoclonal antibody (Signal Transduction Laboratories, Lexington, KY) at 1:1,000 dilution for 1 hour at room temperature, followed by incubation at room temperature for 1 hour each with biotinated anti-mouse IgG secondary antibody and with ABC complex (Vectastain ABC kit; Vector Laboratories, Inc., Burlingame, CA). p27KIP1-positive cells were visualized by incubating the slides with 3,3'-diaminobenzidine, and for light nuclear staining a hematoxylin solution was used. Cells were judged as being apoptotic when they had condensed or fragmented nuclei. At least 200 cells per slide were examined.

Autoradiography

[Methyl-3H]thymidine (Amersham, Buckinghamshire, UK) was added to the culture medium at a final concentration of 37 KBq/ml. The cells were pulse-labeled for 1 hour, washed with centrifugation once, and attached to a glass slide by means of centrifugation. After immunostaining for p27KIP1, the slides were immersed in emulsion for microautoradiography (LM-1; Amersham), kept in the dark at 4°C for 7 days, and then developed according to the manufacturer’s instructions.

Flow Cytometry

Flow cytometric analysis was performed with FACScan and CellFIT-DNA software (Becton Dickinson). Preparation and staining of nuclei were performed as described by Larsen.15

Western Blot Analysis

The following antibodies were used for Western blot analysis: antibodies against p27KIP1 (K25020) and p21CIP1 (C24420) from Signal Transduction Laboratories; p57KIP2 (SC-1040), p15 (SC-613), CDK2 (SC-163), CDK4 (SC-260), and cyclin A (SC-239) from Santa Cruz Biotechnology (Santa Cruz, CA); cyclin E (NCL-CYCLIN E) from Novocastra Laboratories (Newcastle, UK); p16 (13381A) from PharMingen (San Diego, CA); and cyclin D1 (MD-17-3) from Medical and Biological Laboratories (Nagoya, Japan). Ten micrograms of total cell lysate solubilized in Laemmli’s sample buffer was electrophoresed on 10 or 12.5% sodium dodecyl sulfate-polyacrylamide gels and transferred to a Clear Blot Membrane-P filter (Atto, Tokyo, Japan). The filters were first incubated with the primary antibodies and then with horseradish peroxidase-conjugated secondary antibodies (Amersham). For visualization, an enhanced chemiluminescence system (Amersham) was used.

Immunoprecipitation and in Vitro Kinase Assays

The immunoprecipitation and in vitro kinase assays were performed essentially as described by Zhu and colleagues.16 Briefly, 1 x 106 cells were lysed in 0.1 ml of lysis buffer (50 mmol/L Tris, pH 7.4, 250 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic acid, 1% Nonidet P-40, 50 mmol/L NaF, 0.1 mmol/L Na3VO4, and 1x Complete; Boehringer Mannheim, Mannheim, Germany). The cell extracts were incubated with anti-cyclin E antibody or anti-CDK2 antibody for 1 hour at 4°C. The immune complexes were then collected by incubation with protein A Sepharose CL-4B (50 µl; Pharmacia Biotech, Uppsala, Sweden) for 1 hour at 4°C and with a rocking motion, washed five times with ice-cold lysis buffer or kinase buffer (50 mmol/L Tris-HCl at pH 7.4, 10 mmol/L MgCl2), and used for the subsequent immunoblotting for p27KIP1 and histone H1 kinase assays. The extent of histone H1 phosphorylation was determined by means of sodium dodecyl sulfate-gel electrophoresis and subsequent autoradiography.

Transfection

A full-length cDNA of human p27KIP1 was prepared by polymerase chain reaction using the sense oligonucleotide primer 5'-AAGATGTCAAACGTGCGAG-3' and the anti-sense primer 5'-TTACGTTTGACGTCTTCTG-3'. The resulting polymerase chain reaction products were cloned into pBluescript (Stratagene, La Jolla, CA) and sequenced thoroughly to ensure their integrity. The insert was then transferred into pcDNA3 (Invitrogen, Carlsbad, CA) for sense orientation (pcDNA3-p27KIP1). Transient transfection was performed using a cationic lipid reagent, DMRIE-C (Life Technologies, Inc.), according to the manufacturer’s protocol. Briefly, 2 x 106 cells of ACC-LC-49 were co-transfected with 3.6 µg of the p27KIP1 expression vector together with either 0.4 µg of pEGFP (Clontech, Palo Alto, CA) for detection of transfected cells by enhanced green fluorescence or pMACS 4.1 (Miltenyi Biotec, Auburn, CA) for magnetic isolation of transfected cells. After a 48-hour incubation, cells were transferred to complete or isoleucine-free RPMI 1640 medium supplemented with dialyzed 5% FCS and 0.65% methylcellulose, and incubated for a further 48 hours. The cells were then harvested, stained with 4,6-diamidino-2-phenylindole, and examined with a Nikon Fluophoto microscope (Nikon Co., Tokyo, Japan). At least 100 green fluorescence protein (GFP)-positive cells per slide were examined, and cells with condensed or fragmented nuclei were judged to be affected by apoptotic cell death. For confirmation of exogenous p27KIP1 expression, CD4-positive transfected cells were magnetically isolated with a MACSelect4 transfected cell selection kit (Miltenyi Biotec) and the cell lysates electrophoresed and immunoblotted.

Oligonucleotide treatment was performed to reduce the endogenous p27KIP1 expression in ACC-LC-48 cells. The sequences of antisense and mismatch p27KIP1 C-propyne-modified phosphorothioates were 5'-UGGCUCUCCUGCGCC-3' and 5'-UCCCUUUGGCGCGCC-3' (Kurabo, Japan), respectively.17 Transfection was performed with a cytofectin reagent (Gilead Sciences, Foster City, CA) according to the manufacturer’s protocol. After a 24-hour incubation, cells were transferred to either complete or isoleucine-free RPMI 1640 medium, both supplemented with dialyzed 5% FCS and 0.65% methylcellulose, and incubated for a further 72-hour period. The cells were harvested and examined for apoptotic cell death as described above. Reduced expression of p27KIP1 was confirmed by means of Western blot analysis using the whole cell lysate 24 hours after transfer to complete or isoleucine-free medium.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Expression of p27KIP1 in SCLC Cells Accumulates at the G0/G1 Phase and Decreases before Progression to the S Phase in Response to Extracellular Signals

To examine the level of p27KIP1 expression and its relationship with the cell cycle phase, five nonsynchronized cultured SCLC cell lines were doubly labeled with an anti-p27KIP1 antibody and [3H]thymidine. As shown in Table 1 , 31.4 to 52.1% of the cells of four of the SCLC cell lines showed markedly increased p27KIP1 expression in line with the results of our previous immunohistochemical examination of SCLC specimens in vivo. The remaining cell line, ACC-LC-49, poorly expressed p27KIP1. In all cell lines examined, it was evident that [3H]thymidine incorporation was confined exclusively to p27KIP1-negative cells. The observed strictly reciprocal relationship between p27KIP1 positivity and [3H]thymidine incorporation could also be confirmed in in vivo tumors propagated in SCID mice after subcutaneous injection of ACC-LC-35 or ACC-LC-48 cells (Table 1) .


View this table:
[in this window]
[in a new window]
  		Table 1. Relationship between Expression of p27KIP1 and DNA Synthesis (S Phase) in Five Human SCLC Cell Lines

 
The relationship between p27KIP1 expression and cell cycle phase was examined by using ACC-LC-48 as a representative SCLC cell line. Because our preliminary experiment showed that ACC-LC-48 could not be arrested at the G0/G1 phase, even in the RPMI 1640 medium without FCS, perhaps because of autocrine stimulation as is sometimes seen in SCLC (data not shown), we used an isoleucine-free RPMI 1640 medium as an alternative previously reported by Ley and Tobey.18 Approximately 85% of the cells became p27KIP1-positive and arrested at the G0/G1 phase when they were incubated for 72 hours in the isoleucine-free medium (Figure 1) . Release from cell cycle arrest by replacing the isoleucine-free medium with a complete one resulted in a rapid fall in p27KIP1 expression and ~65% of the cells became p27KIP1-negative 16 hours later. After reduction in p27KIP1 expression, cells at the G0/G1 phase began to progress to the S phase around 16 hours after replacement with the complete medium and cells at the S phase gradually increased thereafter. These results indicate that p27KIP1 in SCLC cells accumulates at the G0/G1 phase and decreases before progression to the S phase.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1. Cell cycle phase-dependent p27KIP1 expression in ACC-LC-48. A rapid decrease in p27KIP1 expression and subsequent gradual cell cycle progression to the S phase is apparent in response to release from cell cycle arrest.

 
Highly Expressed p27KIP1 in SCLC Is Biochemically Functional

We next examined whether p27KIP1 in SCLC is functional in conjunction with an inhibition of cyclin-CDK complexes. It was noted that p27KIP1 was greatly elevated after incubation in the isoleucine-free medium for 24 hours (Figure 2A) , whereas a significant reduction of cyclin A was also observed. In contrast, CDK2, CDK4, cyclin D1, cyclin E, p15, p16, p21CIP1, and p57KIP2 were expressed at similar levels in both complete and isoleucine-free media. The quantity of CDK2- or cyclin E-associated p27KIP1, as well as the histone H1 kinase activity of cyclin-CDK complexes containing CDK2 or cyclin E, were also examined. It was found that CDK2- or cyclin E-associated p27KIP1 increased as a result of incubation in the isoleucine-free medium (Figure 2B) . Concurrently with this increase, the histone H1 kinase activity associated with CDK2 or cyclin E was greatly diminished to an almost undetectable level (Figure 2C) . These results indicate that p27KIP1 in SCLC retains its binding capabilities as well as inhibitory activities, suggesting that it functions normally in cell cycle regulation. The reduction in cyclin A might be a consequence of inefficient cell cycle progression caused by deficiency of CDK2-cyclin E activity. Our study also implicates p27KIP1 as a molecule involved in cell cycle arrest because of a lack of nutrient factors, thus identifying the mechanism which had remained unclear since the initial observation by Ley and Tobey.18



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. Expression of cell cycle regulators and biochemical analysis of the activity of p27KIP1 in ACC-LC-48. A: Western blot analysis of total cell lysates. p27KIP1 expression significantly increases in the isoleucine-free medium. Other cell cycle regulators except for cyclin A are similarly expressed in both complete and isoleucine-free media. B: Western blot analysis of CDK2- or cyclin E-associated p27KIP1. Increased association of p27KIP1 with CDK2 or cyclin E is evident when cells are cultured in the isoleucine-free medium. C: In vitro kinase assay of a cyclin-CDK complex associated with cyclin E or CDK2. The histone H1 kinase activity associated with CDK2 or cyclin E is greatly diminished to an almost undetectable level after incubation of cells in the isoleucine-free medium for 24 hours. C, complete medium; I, isoleucine-free medium.

 
Induction of p27KIP1 Expression Correlates with Protection of SCLC Cells from Apoptosis under Culture Conditions Unfavorable for Cell Proliferation

SCLC characteristically exhibits numerous apoptotic appearances both in vivo and in vitro, suggesting that its overall growth represents a balance between proliferation and cell death. In the study reported here, we also asked whether p27KIP1 might have any relation to apoptosis in SCLC using ACC-LC-48 as an example of typical SCLCs with a high expression of p27KIP1. ACC-LC-48 showed a gradual increase of only a fraction of p27KIP1-positive cells when cultured in the complete medium, possibly because of progressively unfavorable changes in the microenvironment such as depletion of essential nutrients (Figure 3A) . Incubation in the isoleucine-free medium resulted in a rapid increase in the p27KIP1-positive fraction associated with cell cycle arrest (Figure 3B) . Under both culture conditions, the proportion of apoptotic cells remained small.



View larger version (54K):
[in this window]
[in a new window]
  		Figure 3. No increase in apoptosis in cells expressing p27KIP1. ACC-LC-48 cells were incubated in the complete (A) or isoleucine-free (B) medium for the indicated periods of time. Representative morphologies of nuclei (dark blue) and p27KIP1 expression (brown) on day 2 are shown on the right.

 
ACC-LC-49, which showed unusually weak p27KIP1 expression during continuous growth (Table 1) , was also examined. p27KIP1 positivity did not increase significantly under either complete or isoleucine-free conditions (Figure 4) . However, there was a marked difference with regard to the occurrence of apoptotic cell death. Typical apoptotic cells showing condensed or fragmented nuclei rapidly appeared in the isoleucine-free medium (Figure 4B) and >80% of the cells had also been heavily stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method by day 3 (data not shown). In contrast, there were very few apoptotic cells in the complete medium (Figure 4A) . Putting these results together suggests that induction of p27KIP1 may play a role in the protection of SCLC cells from apoptosis under culture conditions unfavorable for cell growth.



View larger version (54K):
[in this window]
[in a new window]
  		Figure 4. Absence of p27KIP1 induction and increase in apoptosis in ACC-LC-49. ACC-LC-49 cells were incubated in the complete (A) or isoleucine-free (B) medium for the indicated periods of time. Representative morphologies of nuclei (dark blue) and p27KIP1 expression (brown) day 2 are shown on the right. Arrowheads indicate typical apoptotic cells with condensed or fragmented nuclei.

 
SCLCs, which feature poor vascularity relative to their rich cellularity, are thought to be hypoxic in vivo and tumor cell hypoxia is considered as one of the causes of tumor treatment resistance.19,20 We therefore examined whether another unfavorable microenvironment, hypoxia, can induce p27KIP1 expression in SCLC cell lines. Western blot analysis showed that p27KIP1 expression was clearly increased in ACC-LC-48 within 24 hours when cells were placed in a hypoxic environment, resulting in the expression of p27KIP1 at a level similar to that observed under incomplete nutrient conditions (Figure 5) . ACC-LC-48 cells with increased p27KIP1 expression were found to be resistant to apoptosis under hypoxic conditions. In contrast, an increase in apoptotic cells in a hypoxic environment was evident in ACC-LC-49, which did not show a marked induction of p27KIP1.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 5. Reciprocal relationship between p27KIP1 expression and apoptosis in ACC-LC-48 and ACC-LC-49 under hypoxic conditions. A: Increased expression of p27KIP1 after a 24-hour incubation in either complete medium (C), a hypoxic environment (H) or isoleucine-free medium (I). B: No increased apoptosis in ACC-LC-48 cells exhibiting increased p27KIP1 expression induced by hypoxic conditions. C: Increase in apoptosis in ACC-LC-49 cells showing lack of p27KIP1 induction under the same conditions.

 
These results offer further support for the suggestion that induction of p27KIP1 may play a role in the protection of SCLC cells from apoptosis under culture conditions unfavorable for cell growth such as insufficient nutrients and lack of oxygen.

Manipulation of p27KIP1 Expression Alters Susceptibility to Apoptosis of SCLC Cells

To further examine the relationship between anti-apoptotic activity and induction of p27KIP1 in SCLC, a human p27KIP1 cDNA was introduced together with a GFP (green fluorescence protein) expression vector into ACC-LC-49 with a constitutive low expression of p27KIP1 even in the isoleucine-free medium. Two days after transfection, the cells were transferred to either the complete or the isoleucine-free medium, and further incubated for 2 days. As shown in Figure 6 , the introduction of p27KIP1 resulted in a significant increase in surviving GFP-positive cells in the isoleucine-free medium, whereas there was no such augmentation when they were cultured in the complete medium.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 6. Increased survival after transfection of p27KIP1 of ACC-LC-49 cells in the isoleucine-free medium. A: Expression of exogenous p27KIP1 in the transfected cells. VC-C and VC-I represent data obtained with an empty vector and p27KIP1-C and p27KIP1-I, data obtained with sense p27KIP1 in complete and isoleucine-free media, respectively. B: Increased survival of p27KIP1-transfected cells in isoleucine-free medium. Bars indicate mean ± SD of the proportion of surviving cells in GFP-positive transfected cells in three independent transfections. Open bars represent nonapoptotic fractions in the complete, and solid bars those in the isoleucine-free medium. p27KIP1, sense p27KIP1 vector; VC, empty vector. C: Representative pictures showing apoptosis in nontransfected cells but not in a GFP-positive p27KIP1-transfected cell in isoleucine-free medium.

 
A complementary experiment was performed using ACC-LC-48 cells that contain highly inducible p27KIP1. Either an antisense or mismatch oligonucleotide was transfected to ACC-LC-48. After a 1-day incubation of the transfected cells in the complete medium, they were transferred into either the complete or isoleucine-free medium. A significant decrease in the number of nonapoptotic surviving cells was observed in the isoleucine-free medium but not in the complete medium, in association with the reduction in p27KIP1 expression resulting from the antisense p27KIP1 oligonucleotide treatment (Figure 7) . Introduction of the mismatch oligonucleotide did not produce such effects.



View larger version (37K):
[in this window]
[in a new window]
  		Figure 7. Significant reduction of nonapoptotic surviving ACC-LC-48 cells in the isoleucine-free medium as a result of the introduction of an antisense p27KIP1 oligonucleotide. A: Reduced expression of p27KIP1 in cells transfected with antisense (AS) but not in those transfected with mismatch (MM) oligonucleotides. Numbers denote concentrations (nmol/L) used for various oligonucleotide treatments. B: Dose-dependent reduction resulting from the antisense (AS) p27KIP1 oligonucleotide treatment of nonapoptotic surviving cells in isoleucine-free medium. This result was not seen when the mismatch (MM) oligonucleotide was used. Bars indicate mean ± SD for three independent transfections. C, complete medium; I, isoleucine-free medium. C: Representative pictures of cells transfected with either 10 nmol/L antisense (AS) or mismatch (MM) oligonucleotide in isoleucine-free medium.

 
Together, these observations suggest that p27KIP1 may play a role in the protection of SCLC cells from apoptosis under unfavorable conditions for cell growth. It should be noted that our preliminary experiments showed NSCLC cell lines to be rather refractory to the induction of apoptosis after the introduction of antisense p27KIP1 even in the isoleucine-free medium. This suggests that p27KIP1-dependent resistance to apoptosis may, to certain extent, be specific to SCLC cells (unpublished observation).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our previous immunohistochemical examination of p27KIP1 expression in human lung cancers unexpectedly showed a marked increase in virtually all SCLC cases. The study reported here clearly demonstrates that p27KIP1 expression in SCLC cell lines is normally regulated by the extracellular microenvironment and is not constitutively expressed in a tissue culture or in transplanted tumors. We were also able to show that the cyclin E- or CDK2-associated histone H1-kinase activity is markedly inhibited in SCLC cells under culture conditions unfavorable for cell growth, presumably because of a significant increase of p27KIP1 in the cyclin-CDK complexes. Although SCLC is known to frequently carry c-myc amplification and overexpression,1 it was previously reported that in an experimental system using Rat1 cells, c-myc could induce abrogation of growth arrest by sequestering p27KIP1 from the cyclin E-CDK2 complex.13 The present findings, however, suggest that p27KIP1 is functional as a cell cycle regulator not only in normal lung epithelial cells12 but also in SCLC cells. It is nevertheless possible that high p27KIP1 expression in SCLC may stoichiometrically titrate out the sequestering action of c-myc and that such changes in the delicate balance might consequently induce growth arrest despite myc overexpression.

One of the characteristic histological features of SCLC tumors is the presence of patches of massive cell death, suggesting their susceptibility to apoptosis.2 SCLC shows very rich cellularity together with relatively poor vascularity, which is possibly an architectural prerequisite for insufficient blood supply and low oxygen pressure.19,20 Our study suggests that p27KIP1 can confer on SCLC cells resistance to apoptosis because of an unfavorable microenvironment. It is possible that expression of p27KIP1 in SCLC cells in vivo may be a reflection of unfavorable growth conditions such as insufficient nutrients and low tissue oxygen pressure as shown in vitro in our study. Thus, p27KIP1 might function as a remaining gatekeeper in SCLC cells, which show neuroendocrine differentiation, harbor multiple genetic defects including invariable Rb inactivation,21 and very frequent p53 mutations.22 In this regard, it has been suggested that p27KIP1 may play a part in protecting cells and tissues from inflammatory injury by acting as a safeguard against excessive cell proliferation and apoptosis.23 A similar protective function of p27KIP1 was also implicated in growth factor-deprived fibroblasts from p27KIP1 null mice.24 In addition, it may be of interest that a previous study of ours suggested a possible link between high expression of p27KIP1 and neuroendocrine differentiation of SCLC cells, because prominent apoptosis was reported to be elicited in neuronal cells of Ink4d- and p27KIP1-double-knockout mice,25 which can be viewed as reminiscent of p27KIP1-deprived SCLC cells carrying Rb mutations in terms of cell cycle control.

SCLC is generally very sensitive to chemotherapeutic agents and irradiation, but recurrence is quite frequent, indicating inadequate eradication of tumor cells by currently available therapeutic modalities.26 The existence of quiescent cells such as hypoxic cells is considered to be one of the multifactorial causes of tumor treatment resistance. For this reason, the results presented here warrant further studies aiming at a thorough elimination of the residual SCLC cells by forced reduction of the p27KIP1 expression level. Potential strategies for such novel therapeutics may well include p27KIP1 antisense oligonucleotides and viral vectors as well as agents that selectively enhance degradation of p27KIP1. It is also worth noting that an association between induction of p27KIP1 and drug resistance was shown in a murine mammary tumor cell line and that p27KIP1 antisense oligonucleotides in combination with conventional anticancer drugs enhanced apoptosis.17,27 Such a combinatorial treatment may prove to be useful as an adjunct therapy for the treatment of SCLC.


   Footnotes
 
Address reprint requests to Dr. Takashi Takahashi, Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. E-mail: tak{at}aichi-cc.pref.aichi.jp

Supported in part by a grant-in-aid for Scientific Research on Priority Areas and a grant-in-aid for Scientific Research (C) from the Ministry of Education, Science, Sports, and Culture, Japan; a grant-in-aid for the Second Term Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan; and by a grant from the Smoking Research Foundation.

Accepted for publication September 14, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Minna JD, Sekido Y, Fong KM, Gazdar AF: Cancer of the lung. DeVita VT Hellman S Rosenberg SA eds. Cancer Principles and Practice of Oncology. 1997, :pp 849-949 Lippincott-Raven, Philadelphia
  2. Travis WD, Linder J, Mackay B: Classification, histology, cytology, and electron microscopy. Pass HI Mitchell JB Johnson DH Turisi AT eds. Lung Cancer: Principles and Practice. 1996, :pp 361-395 Lippincott-Raven, Philadelphia
  3. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677[Abstract/Free Full Text]
  4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440[Abstract/Free Full Text]
  5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson D: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756[Medline]
  6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancer. Nat Med 1995, 1:686-692[Medline]
  7. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55:514-517[Abstract/Free Full Text]
  8. Kondo M, Matsuoka S, Uchida K, Osada H, Nagatake M, Takagi K, Harper JW, Takahashi T, Elledge SJ, Takahashi T: Selective maternal-allele loss in human lung cancers of maternally expressed p57KIP2 gene at 11p15.5. Oncogene 1996, 12:1365-1368[Medline]
  9. Coats S, Flanagan M, Nourse J, Roberts JM: Requirement of p27KIP1 for restriction point control of the fibroblast cell cycle. Science 1996, 272:877-880[Abstract]
  10. Ponce-Castañeda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C: p27KIP1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995, 55:1211-1214[Abstract/Free Full Text]
  11. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995, 55:2266-2269[Abstract/Free Full Text]
  12. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T, Takahashi T: p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998, 58:1042-1047[Abstract/Free Full Text]
  13. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: Growth arrest by the cyclin-dependent kinase inhibitor p27KIP1 is abrogated by c-Myc. EMBO J 1996, 15:6595-6604[Medline]
  14. Sekido Y, Takahashi T, Mäkelä TP, Obata Y, Ueda R, Hida T, Hibi K, Shimokata K, Alitalio K, Takahashi T: Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Mol Cell Biol 1992, 12:1747-1754[Abstract/Free Full Text]
  15. Larsen JK: Washless double staining of a nuclear antigen (Ki-67 or bromodeoxyuridine) and DNA in unfixed nuclei. Method in cell biology. Flow cytometry, vol 33. Edited by Z Darzynkiewicz, HA Crissman. San Diego, Academic Press, 1990, 227–234
  16. Zhu X, Ohtsubo M, Böhmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 1996, 133:391-403[Abstract/Free Full Text]
  17. St Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996, 2:1204-1210[Medline]
  18. Ley KD, Tobey RA: Regulation of initiation of DNA synthesis in Chinese hamster cells. II Induction of DNA synthesis and cell division by isoleucine and glutamine in G1-arrested cells in suspension culture. J Cell Biol 1970, 47:453-459[Abstract/Free Full Text]
  19. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C, Chapman JD: Measurement of hypoxia in human tumors by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer 1996, 74(Suppl XXVII):S209-S212
  20. Urtasun RC, Palmer M, Kinney B, Belch A, Hewitt J, Hanson J: Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study. Int J Radiat Oncol Biol Phys 1998, 40:337-342[Medline]
  21. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988, 241:353-357[Abstract/Free Full Text]
  22. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-494[Abstract/Free Full Text]
  23. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ: The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998, 4:575-580[Medline]
  24. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ: Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27Kip1. J Clin Invest 1999, 103:597-604[Medline]
  25. Zingy F, Cunningham JJ, Sherr CJ, Jogal S, Smeyne RJ, Roussel MF: Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci USA 1999, 96:13462-13467[Abstract/Free Full Text]
  26. Ihde DC, Pass HI, Glatstein E: Small cell lung cancer. DeVita VT Hellman S Rosenberg SA eds. Cancer Principles and Practice of Oncology. 1997, :911-949 Lippincott-Raven, Philadelphia
  27. St Croix B, Kerbel RS: Cell adhesion and drug resistance in cancer. Curr Opin Oncol 1997, 9:549-556[Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob, and S. Majumder
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
J. Biol. Chem., October 31, 2008; 283(44): 29897 - 29903.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
T. R. Kataoka, Y. Tsukamoto, M. Matsumura, A. Miyake, S. Kamiura, S. Ishiguro, and Y. Nishizawa
Expression of p21Cip1/Waf1 and p27Kip1 in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix
International Journal of Surgical Pathology, January 1, 2008; 16(1): 11 - 15.
[Abstract] [PDF]

Home page
 JCOHome page
M. Filipits, R. Pirker, A. Dunant, S. Lantuejoul, K. Schmid, A. Huynh, V. Haddad, F. Andre, R. Stahel, J.-P. Pignon, et al.
Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program
J. Clin. Oncol., July 1, 2007; 25(19): 2735 - 2740.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Y. Wu, S. E. Wang, M. E. Sanders, I. Shin, F. Rojo, J. Baselga, and C. L. Arteaga
Reduction of Cytosolic p27Kip1 Inhibits Cancer Cell Motility, Survival, and Tumorigenicity
Cancer Res., February 15, 2006; 66(4): 2162 - 2172.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Eguchi, S Carpentier, S S Kim, and S F Moss
p27kip1 regulates the apoptotic response of gastric epithelial cells to Helicobacter pylori
Gut, June 1, 2004; 53(6): 797 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. Eymin and E. Brambilla
The yin and the yang of p27Kip1 as a target for cancer therapy
Eur. Respir. J., May 1, 2004; 23(5): 663 - 664.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Ishii, M. Fujishiro, M. Masuda, Y. Goshima, H. Kitamura, S. Teramoto, and T. Matsuse
Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells
Eur. Respir. J., May 1, 2004; 23(5): 665 - 670.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
E. A. Davison, C. S. L. Lee, M. J. Naylor, S. R. Oakes, R. L. Sutherland, L. Hennighausen, C. J. Ormandy, and E. A. Musgrove
The Cyclin-Dependent Kinase Inhibitor p27 (Kip1) Regulates Both DNA Synthesis and Apoptosis in Mammary Epithelium But Is Not Required for Its Functional Development during Pregnancy
Mol. Endocrinol., December 1, 2003; 17(12): 2436 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Haruki, T. Harano, A. Masuda, T. Kiyono, T. Takahashi, Y. Tatematsu, S. Shimizu, T. Mitsudomi, H. Konishi, H. Osada, et al.
Persistent Increase in Chromosome Instability in Lung Cancer : Possible Indirect Involvement of p53 Inactivation
Am. J. Pathol., October 1, 2001; 159(4): 1345 - 1352.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masuda, A.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masuda, A.
Right arrow Articles by Takahashi, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS